Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 04:12:53时区推断·⟳ 抓取 04:14:14·⚡ 决策 08-04 12:21:15 +8h07m·84.3 天前
BWX Technologies拟最高8亿美元出售医疗业务给Nordic Capital
出售对价最高8亿美元，约占BWXT 159.2亿美元市值的5.0%，方向上有利于聚焦核国防和商用核电主业。
📄 原文Investing.com↗ 原文
BWXT to sell medical business to Nordic Capital for $800M
Dow posts first record close in nearly a month as stocks rally to kick off August LYNCHBURG, Va. - BWX Technologies (NY…
不做 BWX Technologies（BWXT.US）
出售最高8亿美元约占市值5.0%，方向偏正但完成期到2026年底、对价结构和税后收益未披露，且剥离盈利医疗业务带来抵消，短线edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Investing转述公司新闻稿，披露BWXT拟将医疗业务以最高8亿美元出售给Nordic Capital。市场反应:BWXT 08-03常规收盘173.79美元，较前收涨3.02%；公告发生在收盘后，非公告后连续交易确认。
关键理由
- 出售对价最高8亿美元，约占BWXT 159.2亿美元市值的5.0%，方向上有利于聚焦核国防和商用核电主业。
- 交易预计到2026年底才完成且需监管审批，并保留少数股权，现金流入和估值释放不在当前1-3个交易日完全兑现。
- 被出售医疗业务自2018年收购以来收入约扩大三倍且盈利改善，剥离同时也减少一个增长业务，短线净增量不够单边。
主要风险
- 对价为“up to 800 million”且未披露现金/或有结构、税费和医疗业务当前EBITDA，重大性和净收益难以精算。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
内部KB未命中该医疗业务当前收入、EBITDA或税后出售收益的有效量化证据，削弱追多把握。
检索:BWX Technologies sell medical business Nordic Capital $800 million medical segment revenue profitability - 做多前查反向 · 来源 web · 影响 weakens
Web搜索未稳定返回公司出售医疗业务原始新闻稿正文，当前可用证据主要来自聚合稿；未发现额外可量化增量。
检索:BWX Technologies sell medical business Nordic Capital up to $800 million August 3 2026 medical business revenue
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,798 字
Dow posts first record close in nearly a month as stocks rally to kick off August
LYNCHBURG, Va. - BWX Technologies (NYSE:BWXT) announced today it has entered into a definitive agreement to sell its medical business to Nordic Capital for up to $800 million, according to a press release statement.
The transaction includes BWXT Medical and the Kinectrics stable medical isotopes business. BWXT will retain a minority ownership stake in the divested business and continue providing specialized isotope and radiochemical expertise under the agreement.
The sale allows BWXT to focus resources and capital on its nuclear national security and commercial nuclear power operations. The medical business will operate under Nordic Capital’s ownership, focusing on radiopharmaceuticals for diagnostic imaging and radiotherapeutic treatments.
"Since acquiring the medical business in 2018, we have roughly tripled revenue, improved profitability and significantly expanded the product portfolio, including novel therapeutic isotopes," said Rex D. Geveden, BWXT president and chief executive officer.
Christian Hedegaard, partner at Nordic Capital Advisors, stated the firm sees potential to scale the business and expand access to radiopharmaceutical therapy. Nordic Capital manages approximately EUR 39 billion in assets and invests in middle-market companies across Northern Europe and North America.
The transaction is subject to customary regulatory approvals and is expected to close by the end of 2026.
Solomon Partners is serving as exclusive financial advisor to BWXT, with Stikeman Elliott as legal counsel. Kirkland & Ellis LLP and McCarthy Tétrault are legal counsel for Nordic Capital.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
LYNCHBURG, Va. - BWX Technologies (NYSE:BWXT) announced today it has entered into a definitive agreement to sell its medical business to Nordic Capital for up to $800 million, according to a press release statement.
The transaction includes BWXT Medical and the Kinectrics stable medical isotopes business. BWXT will retain a minority ownership stake in the divested business and continue providing specialized isotope and radiochemical expertise under the agreement.
The sale allows BWXT to focus resources and capital on its nuclear national security and commercial nuclear power operations. The medical business will operate under Nordic Capital’s ownership, focusing on radiopharmaceuticals for diagnostic imaging and radiotherapeutic treatments.
"Since acquiring the medical business in 2018, we have roughly tripled revenue, improved profitability and significantly expanded the product portfolio, including novel therapeutic isotopes," said Rex D. Geveden, BWXT president and chief executive officer.
Christian Hedegaard, partner at Nordic Capital Advisors, stated the firm sees potential to scale the business and expand access to radiopharmaceutical therapy. Nordic Capital manages approximately EUR 39 billion in assets and invests in middle-market companies across Northern Europe and North America.
The transaction is subject to customary regulatory approvals and is expected to close by the end of 2026.
Solomon Partners is serving as exclusive financial advisor to BWXT, with Stikeman Elliott as legal counsel. Kirkland & Ellis LLP and McCarthy Tétrault are legal counsel for Nordic Capital.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。